221 related articles for article (PubMed ID: 28232476)
21. Metastatic role of mammalian target of rapamycin signaling activation by chemoradiotherapy in advanced rectal cancer.
Shiratori H; Kawai K; Okada M; Nozawa H; Hata K; Tanaka T; Nishikawa T; Shuno Y; Sasaki K; Kaneko M; Murono K; Emoto S; Ishii H; Sonoda H; Ushiku T; Ishihara S
Cancer Sci; 2020 Apr; 111(4):1291-1302. PubMed ID: 31997546
[TBL] [Abstract][Full Text] [Related]
22. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW
Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778
[TBL] [Abstract][Full Text] [Related]
23. Uterine sarcomas: a review.
D'Angelo E; Prat J
Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
[TBL] [Abstract][Full Text] [Related]
24. High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy.
Liu H; Du L; Wang R; Wei C; Liu B; Zhu L; Liu P; Liu Q; Li J; Lu SL; Xiao J
Oncotarget; 2015 May; 6(13):11477-91. PubMed ID: 25909167
[TBL] [Abstract][Full Text] [Related]
25. Epigallocatechin-3-gallate potentiates curcumin's ability to suppress uterine leiomyosarcoma cell growth and induce apoptosis.
Kondo A; Takeda T; Li B; Tsuiji K; Kitamura M; Wong TF; Yaegashi N
Int J Clin Oncol; 2013 Jun; 18(3):380-8. PubMed ID: 22350026
[TBL] [Abstract][Full Text] [Related]
26. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of the PI3K catalytic subunit p110δ underlies elevated S6 phosphorylation and protein synthesis in an individual with autism from a multiplex family.
Poopal AC; Schroeder LM; Horn PS; Bassell GJ; Gross C
Mol Autism; 2016; 7():3. PubMed ID: 26770665
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine and Selected mTOR Inhibitors in Uterine Sarcomas and Carcinosarcoma Cells- an Isobolographic Analysis.
Bobiński M; Okła K; Łuszczki J; Bednarek W; Wawruszak A; Moreno-Bueno G; Garcia-Sanz P; Dmoszyńska-Graniczka M; Tarkowski R; Kotarski J
Int J Med Sci; 2020; 17(18):2987-2997. PubMed ID: 33173419
[No Abstract] [Full Text] [Related]
29. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
30. From PTEN loss of expression to RICTOR role in smooth muscle differentiation: complex involvement of the mTOR pathway in leiomyosarcomas and pleomorphic sarcomas.
Gibault L; Ferreira C; Pérot G; Audebourg A; Chibon F; Bonnin S; Lagarde P; Vacher-Lavenu MC; Terrier P; Coindre JM; Aurias A
Mod Pathol; 2012 Feb; 25(2):197-211. PubMed ID: 22080063
[TBL] [Abstract][Full Text] [Related]
31. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus.
Nola M; Babić D; Ilić J; Marusić M; Uzarević B; Petrovecki M; Sabioncello A; Kovac D; Jukić S
Cancer; 1996 Dec; 78(12):2543-50. PubMed ID: 8952563
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
Setsu N; Kohashi K; Fushimi F; Endo M; Yamamoto H; Takahashi Y; Yamada Y; Ishii T; Yokoyama K; Iwamoto Y; Oda Y
Cancer; 2013 Oct; 119(19):3504-13. PubMed ID: 23861137
[TBL] [Abstract][Full Text] [Related]
33. Different cytoplasmic/nuclear distribution of S6 protein phosphorylated at S240/244 and S235/236.
Rosner M; Fuchs C; Dolznig H; Hengstschläger M
Amino Acids; 2011 Feb; 40(2):595-600. PubMed ID: 20625781
[TBL] [Abstract][Full Text] [Related]
34. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
Cuppens T; Moisse M; Depreeuw J; Annibali D; Colas E; Gil-Moreno A; Huvila J; Carpén O; Zikán M; Matias-Guiu X; Moerman P; Croce S; Lambrechts D; Amant F
Int J Cancer; 2018 Mar; 142(6):1230-1243. PubMed ID: 29063609
[TBL] [Abstract][Full Text] [Related]
35. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
Podsypanina K; Lee RT; Politis C; Hennessy I; Crane A; Puc J; Neshat M; Wang H; Yang L; Gibbons J; Frost P; Dreisbach V; Blenis J; Gaciong Z; Fisher P; Sawyers C; Hedrick-Ellenson L; Parsons R
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10320-5. PubMed ID: 11504907
[TBL] [Abstract][Full Text] [Related]
36. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
37. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
38. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond.
Croce S; Chibon F
Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852
[TBL] [Abstract][Full Text] [Related]
39. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
40. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
